^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zotiraciclib (TG02)

    i
    Company:
    Adastra Pharma, Cothera Biosci, S*BIO
    Drug class:
    JAK2 inhibitor, FLT3 inhibitor, CDK9 inhibitor, CDK7 inhibitor, CDK2 inhibitor, CDK1 inhibitor, CDK5 inhibitor, ERK5 inhibitor
    Related drugs:
    Apply
    A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/16/2023
    Primary completion :
    08/01/2025
    Completion :
    08/02/2029
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    zotiraciclib (TG02)
    Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) (NCT03224104)
    Phase 1
    European Organisation for Research and Treatmen...
    Completed
    Last update posted :
    05/31/2022
    Initiation :
    06/12/2018
    Primary completion :
    05/05/2022
    Completion :
    05/05/2022
    IDH1 • IDH2 • MCL1 • CDK9
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • zotiraciclib (TG02)
    Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (NCT02942264)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/28/2021
    Initiation :
    12/14/2016
    Primary completion :
    08/26/2020
    Completion :
    08/26/2020
    TP53 • ATRX
    |
    temozolomide • zotiraciclib (TG02)